Evidence map›Paper›PMID 38339377›Full record

ReviewCancers2024

Decoding the Tumour Microenvironment: Molecular Players, Pathways, and Therapeutic Targets in Cancer Treatment.

Eleonora Malavasi, Manuel Adamo, Elisa Zamprogno, Viviana Vella, Georgios Giamas, Teresa Gagliano

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Eleonora MalavasiCancer Cell Signalling Laboratory, Department of Medicine, University of Udine, 33100 Udine, Italy.ORCID 0000-0002-6689-230X
Manuel AdamoCancer Cell Signalling Laboratory, Department of Medicine, University of Udine, 33100 Udine, Italy.ORCID 0009-0009-3706-2225
Elisa ZamprognoCancer Cell Signalling Laboratory, Department of Medicine, University of Udine, 33100 Udine, Italy.
Viviana VellaSchool of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.ORCID 0000-0003-1000-3443
Georgios GiamasSchool of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.ORCID 0000-0002-4417-2707
Teresa GaglianoCancer Cell Signalling Laboratory, Department of Medicine, University of Udine, 33100 Udine, Italy.
University of Udine · ITUniversity of Sussex · GB

Funding

Departmental Strategic Plan (PSD) of the University of Udine-Interdepartmental Project on Healthy Ageing (2020-25) Departmental Strategic Plan (PSD) of the University of Udine-Interdepartmental Project on Healthy Ageing (2020-25)
6 · The paper itself

Abstract

The tumour microenvironment (TME) is a complex and constantly evolving collection of cells and extracellular components. Cancer cells and the surrounding environment influence each other through different types of processes. Characteristics of the TME include abnormal vasculature, altered extracellular matrix, cancer-associated fibroblast and macrophages, immune cells, and secreted factors. Within these components, several molecules and pathways are altered and take part in the support of the tumour. Epigenetic regulation, kinases, phosphatases, metabolic regulators, and hormones are some of the players that influence and contribute to shaping the tumour and the TME. All these characteristics contribute significantly to cancer progression, metastasis, and immune escape, and may be the target for new approaches for cancer treatment.

Indexed as

cancercytokinesepigeneticshormoneskinasesmetabolismphosphatasestumour microenvironment

Identifiers

PMID38339377
PMCPMC10854614
OpenAlexW4391404296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.